A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients

NCT00384137 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
128
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Astellas Pharma Inc